On October 20, Oracle and AstraZeneca announced that they have reached a non-binding agreement to explore the use of artificial intelligence and real-world data to identify patients eligible for clinical trials, speed up the generation of medical evidence, and integrate relevant research results into daily diagnosis and treatment processes. The two sides will combine AstraZeneca's expertise in research and treatment with Oracle's data, cloud computing, AI, and clinical workflow technology. The two sides are initially considering exploring applications in the fields of oncology, cardiovascular, renal and metabolic diseases, respiratory and immune diseases, and rare diseases, and plan to establish joint treatment mechanisms and efficacy evaluation indicators to evaluate whether related programs can be extended to more disease fields and regions. This cooperation is still in the exploration stage, and no specific implementation schedule has been announced.

On October 20, Oracle and AstraZeneca announced that they have reached a non-binding agreement to explore the use of artificial intelligence and real-world data to identify patients eligible for clinical trials, speed up the generation of medical evidence, and integrate relevant research results into daily diagnosis and treatment processes. The two sides will combine AstraZeneca's expertise in research and treatment with Oracle's data, cloud computing, AI, and clinical workflow technology. The two sides are initially considering exploring applications in the fields of oncology, cardiovascular, renal and metabolic diseases, respiratory and immune diseases, and rare diseases, and plan to establish joint treatment mechanisms and efficacy evaluation indicators to evaluate whether related programs can be extended to more disease fields and regions. This cooperation is still in the exploration stage, and no specific implementation schedule has been announced.